Breyanzi^®- From Mode of Action to administration

Duration 5 min, audio/text in English

Breyanzi® is manufactured from the patient’s own CD8- and CD4-positive T cells, which are modified with a viral vector to express a CD19-directed chimeric antigen receptor (CAR). When the CAR-T cell binds to CD19, T cell activation and proliferation are induced, along with secretion of inflammatory cytokines and cytotoxic killing of cancer cells.¹

Reference: 

1. Breyanzi® SMPC